These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 19638453

  • 1. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE.
    Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 4. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [Abstract] [Full Text] [Related]

  • 5. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A, Zeng Q, Wang CY.
    Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J, Guan J, Chang I, Chen X, Han D, Wang CY.
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
    Li C, Johnson DE.
    Cancer Lett; 2012 Jan 01; 314(1):102-7. PubMed ID: 21993018
    [Abstract] [Full Text] [Related]

  • 10. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
    Chakravarti N, Myers JN, Aggarwal BB.
    Int J Cancer; 2006 Sep 15; 119(6):1268-75. PubMed ID: 16642480
    [Abstract] [Full Text] [Related]

  • 11. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z.
    Mol Cancer; 2019 Mar 11; 18(1):38. PubMed ID: 30857539
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF.
    Oral Oncol; 2012 Jul 11; 48(7):585-93. PubMed ID: 22342571
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
    Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, Ho CT, Way TD.
    J Agric Food Chem; 2012 Mar 14; 60(10):2480-9. PubMed ID: 22313388
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.
    Cell Death Dis; 2014 Oct 23; 5(10):e1489. PubMed ID: 25341043
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
    Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR.
    Carcinogenesis; 2009 Nov 23; 30(11):1848-56. PubMed ID: 19762335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.